See more : AXIS Capital Holdings Limited (AXS-PE) Income Statement Analysis – Financial Results
Complete financial analysis of Harvard Bioscience, Inc. (HBIO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Harvard Bioscience, Inc., a leading company in the Medical – Instruments & Supplies industry within the Healthcare sector.
You may be interested
- Ferrovial SE (FER.MC) Income Statement Analysis – Financial Results
- VP Bank AG (VUPPF) Income Statement Analysis – Financial Results
- Zhejiang Meilun Elevator Co., Ltd. (603321.SS) Income Statement Analysis – Financial Results
- Altiplano Metals Inc. (APN.V) Income Statement Analysis – Financial Results
- Kiwi Property Group Limited (KPG.NZ) Income Statement Analysis – Financial Results
Harvard Bioscience, Inc. (HBIO)
Industry: Medical - Instruments & Supplies
Sector: Healthcare
Website: https://www.harvardbioscience.com
About Harvard Bioscience, Inc.
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development in the United States and internationally. The company offers cellular and molecular technology instruments, such as syringe and peristaltic pump products, as well as a range of instruments and accessories for tissue and organ-based lab research, including surgical products, infusion systems, and behavior research systems; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, and electroporation and electrofusion instruments. It also engages in the development and manufacture of precision scientific measuring instrumentation and equipment, which cover data acquisition systems with custom amplifier configurations for cellular analysis, micro electrode array solutions for in vivo recordings, and vitro-systems for extracellular recordings; and offers preclinical products. The company markets its products through sales organizations, websites, catalogs, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories, as well as to contract research organizations, academic labs, and government researchers. It primarily sells its products under Harvard Apparatus, DSI, Ponemah, Buxco, Biochrom, BTX, and MCS brand names. The company was founded in 1901 and is headquartered in Holliston, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 112.25M | 113.34M | 118.90M | 102.10M | 116.18M | 120.77M | 101.88M | 104.52M | 108.66M | 108.66M | 105.17M | 111.17M | 108.86M | 108.18M | 85.77M | 88.05M | 83.41M | 76.18M | 67.43M | 92.60M | 87.14M | 57.38M | 40.87M | 30.57M | 26.18M | 12.15M |
| Cost of Revenue | 46.18M | 52.52M | 51.25M | 44.06M | 51.85M | 57.59M | 54.29M | 56.11M | 59.94M | 59.32M | 57.48M | 58.75M | 58.60M | 56.40M | 44.09M | 45.89M | 43.16M | 38.09M | 34.16M | 46.52M | 43.73M | 28.82M | 20.64M | 15.10M | 12.72M | 5.35M |
| Gross Profit | 66.07M | 60.82M | 67.65M | 58.04M | 64.32M | 63.18M | 47.60M | 48.42M | 48.72M | 49.34M | 47.70M | 52.42M | 50.26M | 51.78M | 41.68M | 42.16M | 40.25M | 38.09M | 33.28M | 46.07M | 43.41M | 28.56M | 20.23M | 15.47M | 13.46M | 6.80M |
| Gross Profit Ratio | 58.86% | 53.66% | 56.90% | 56.85% | 55.37% | 52.31% | 46.72% | 46.32% | 44.84% | 45.41% | 45.35% | 47.15% | 46.17% | 47.86% | 48.60% | 47.88% | 48.25% | 50.00% | 49.35% | 49.76% | 49.82% | 49.77% | 49.50% | 50.61% | 51.40% | 55.97% |
| Research & Development | 11.76M | 12.33M | 10.80M | 8.69M | 10.72M | 10.99M | 5.65M | 5.39M | 6.42M | 4.88M | 4.15M | 7.32M | 5.43M | 4.71M | 4.40M | 4.05M | 3.71M | 3.15M | 2.95M | 7.19M | 6.26M | 4.15M | 3.18M | 1.53M | 1.19M | 325.00K |
| General & Administrative | 22.78M | 24.49M | 24.31M | 23.51M | 22.76M | 21.38M | 18.58M | 20.95M | 19.83M | 16.83M | 19.94M | 19.70M | 18.06M | 17.64M | 15.11M | 26.10M | 25.18M | 24.55M | 20.74M | 31.06M | 26.78M | 18.89M | 14.52M | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 24.11M | 25.04M | 24.64M | 19.92M | 23.26M | 24.44M | 21.04M | 20.49M | 20.58M | 18.23M | 17.33M | 19.17M | 17.47M | 16.35M | 11.76M | 10.97M | 10.35M | 9.50M | 8.11M | 16.82M | 15.38B | 8.44B | 4.84B | 0.00 | 0.00 | 0.00 |
| SG&A | 46.89M | 49.53M | 48.95M | 43.43M | 46.02M | 45.83M | 39.61M | 41.44M | 40.41M | 35.05M | 37.27M | 38.87M | 35.54M | 33.99M | 26.87M | 26.10M | 25.18M | 24.55M | 20.74M | 31.06M | 26.78M | 18.89M | 14.52M | 22.78M | 9.88M | 4.04M |
| Other Expenses | 5.60M | 6.12M | 5.84M | 5.71M | 5.75M | -4.28M | -740.00K | -179.00K | -1.26M | -1.14M | -51.00K | -287.00K | 2.75M | 2.36M | 1.84M | 1.97M | 1.82M | 1.70M | 1.67M | 3.45M | 2.70M | 1.54M | 1.74M | 1.49M | 1.26M | 27.00K |
| Operating Expenses | 64.50M | 67.99M | 65.59M | 57.82M | 62.49M | 62.20M | 47.70M | 49.55M | 49.65M | 42.51M | 44.01M | 48.94M | 43.72M | 41.06M | 33.11M | 32.12M | 30.71M | 29.40M | 25.35M | 41.69M | 35.75M | 24.58M | 19.44M | 25.80M | 12.32M | 4.39M |
| Cost & Expenses | 110.36M | 120.50M | 116.84M | 101.88M | 114.34M | 119.79M | 101.98M | 105.66M | 109.59M | 101.83M | 101.48M | 107.70M | 102.32M | 97.46M | 77.20M | 78.01M | 73.87M | 67.49M | 59.51M | 88.22M | 79.48M | 53.40M | 40.08M | 40.90M | 25.04M | 9.74M |
| Interest Income | 0.00 | 2.55M | 1.54M | 4.83M | 5.41M | 0.00 | 0.00 | 3.00K | 8.00K | 74.00K | 43.00K | 46.00K | 65.00K | 65.00K | 29.00K | 372.00K | 317.00K | 216.00K | 234.00K | 136.00K | 175.99K | 445.67K | 1.36M | 159.85K | 0.00 | 0.00 |
| Interest Expense | 3.59M | 2.25M | 1.54M | 4.83M | 5.41M | 5.37M | 713.00K | 642.00K | 854.00K | 990.00K | 955.00K | 584.00K | 752.00K | 677.00K | 277.00K | 389.00K | 365.00K | 429.00K | 917.00K | 794.00K | 327.23K | 104.18K | 6.87K | 916.21K | 0.00 | 0.00 |
| Depreciation & Amortization | 7.00M | 7.58M | 7.62M | 7.63M | 7.73M | 7.84M | 2.91M | 4.27M | 2.82M | 2.58M | 3.99M | 4.21M | 2.75M | 2.36M | 1.84M | 3.10M | 3.47M | 3.34M | 5.04M | 6.35M | 5.29M | 3.01M | 2.97M | 1.49M | 1.26M | 27.00K |
| EBITDA | 8.03M | 944.00K | 11.31M | 5.49M | 7.50M | 5.36M | -101.00K | 1.80M | 1.73M | 9.29M | 7.67M | 11.68M | 11.95M | 13.80M | 13.14M | 11.14M | 9.53M | 8.69M | 12.96M | 14.73M | 12.95M | 6.99M | 3.76M | -8.84M | 2.39M | 2.44M |
| EBITDA Ratio | 7.16% | -0.92% | 6.09% | 5.02% | 6.21% | 1.73% | 1.57% | 1.35% | 0.59% | 7.69% | 7.29% | 6.69% | 8.59% | 12.15% | 12.18% | 17.61% | 15.50% | 15.89% | 19.37% | 11.39% | 15.17% | 15.61% | 22.79% | 93.51% | 122.81% | 20.07% |
| Operating Income | 1.89M | -7.17M | 1.40M | -585.00K | 1.47M | 984.00K | -101.00K | -3.00M | -1.71M | 6.62M | 1.54M | 3.17M | 6.08M | 10.22M | 8.06M | 8.48M | 9.53M | 8.69M | 7.92M | 4.38M | 7.67M | 1.64M | -4.66M | -10.33M | 1.13M | 2.41M |
| Operating Income Ratio | 1.69% | -6.32% | 1.18% | -0.57% | 1.27% | 0.81% | -0.10% | -2.87% | -1.58% | 6.09% | 1.46% | 2.85% | 5.58% | 9.45% | 9.39% | 9.63% | 11.43% | 11.41% | 11.75% | 4.73% | 8.80% | 2.86% | -11.40% | -33.77% | 4.33% | 19.85% |
| Total Other Income/Expenses | -4.45M | -2.25M | -2.21M | -7.51M | -5.88M | -8.96M | -1.99M | -81.00K | -1.90M | -2.20M | -1.10M | -5.60M | -1.54M | -655.00K | 1.76M | -829.00K | 35.00K | -294.00K | -784.00K | 3.25M | -428.00K | 707.00K | 1.24M | -38.18M | -30.42M | -1.56M |
| Income Before Tax | -2.56M | -9.18M | -140.00K | -7.29M | -5.50M | -8.52M | -2.09M | -3.08M | -3.61M | 4.42M | 435.00K | 2.23M | 4.54M | 9.56M | 9.81M | 7.65M | 9.57M | 8.40M | 7.14M | 3.80M | 7.24M | 2.35M | -3.42M | -48.51M | -29.28M | 854.00K |
| Income Before Tax Ratio | -2.28% | -8.10% | -0.12% | -7.14% | -4.74% | -7.05% | -2.05% | -2.94% | -3.32% | 4.06% | 0.41% | 2.00% | 4.17% | 8.84% | 11.44% | 8.69% | 11.47% | 11.02% | 10.59% | 4.10% | 8.30% | 4.09% | -8.36% | -158.66% | -111.86% | 7.03% |
| Income Tax Expense | 859.00K | 337.00K | 148.00K | 518.00K | -815.00K | -3.68M | -1.22M | 1.23M | 15.43M | 2.06M | -288.00K | 696.00K | 730.00K | -9.45M | 2.67M | 2.24M | 1.97M | 1.78M | 899.00K | 1.47M | 2.98M | 1.61M | 1.79M | 1.36M | 137.48K | 783.00K |
| Net Income | -3.42M | -9.52M | -288.00K | -7.81M | -4.69M | -3.46M | -865.00K | -4.31M | -19.04M | 2.36M | -1.83M | 2.37M | 3.81M | 19.02M | 7.23M | 1.67M | -1.35M | -2.34M | -31.88M | 2.33M | 4.26M | 737.33K | -5.21M | -49.87M | -29.42M | 71.00K |
| Net Income Ratio | -3.04% | -8.40% | -0.24% | -7.65% | -4.03% | -2.87% | -0.85% | -4.12% | -17.52% | 2.17% | -1.74% | 2.13% | 3.50% | 17.58% | 8.43% | 1.90% | -1.62% | -3.07% | -47.27% | 2.52% | 4.89% | 1.28% | -12.74% | -163.11% | -112.38% | 0.58% |
| EPS | -0.08 | -0.23 | -0.01 | -0.20 | -0.12 | -0.10 | -0.03 | -0.13 | -0.57 | 0.07 | -0.06 | 0.09 | 0.13 | 0.66 | 0.24 | 0.05 | -0.04 | -0.08 | -1.05 | 0.08 | 0.14 | 0.03 | -0.20 | -6.23 | -5.25 | -0.01 |
| EPS Diluted | -0.08 | -0.23 | -0.01 | -0.20 | -0.12 | -0.10 | -0.02 | -0.13 | -0.57 | 0.07 | -0.06 | 0.08 | 0.13 | 0.65 | 0.24 | 0.05 | -0.04 | -0.08 | -1.04 | 0.07 | 0.14 | 0.03 | -0.20 | -6.23 | -5.25 | -0.01 |
| Weighted Avg Shares Out | 42.42M | 41.41M | 40.34M | 38.64M | 37.81M | 35.83M | 33.60M | 34.21M | 33.59M | 32.17M | 30.38M | 28.80M | 28.45M | 28.97M | 29.65M | 30.88M | 30.65M | 30.52M | 30.44M | 30.27M | 29.92M | 27.09M | 25.78M | 8.01M | 5.60M | 5.60M |
| Weighted Avg Shares Out (Dil) | 42.42M | 41.41M | 40.34M | 38.64M | 37.81M | 36.45M | 34.75M | 34.21M | 33.59M | 33.24M | 31.91M | 29.79M | 29.82M | 29.41M | 29.95M | 31.35M | 31.41M | 31.15M | 30.78M | 31.10M | 30.71M | 27.60M | 25.78M | 8.01M | 5.60M | 5.60M |
Harvard Bioscience, Inc. (HBIO) Q3 2024 Earnings Call Transcript
Harvard Bioscience, Inc. (NASDAQ:HBIO ) Q3 2024 Results Conference Call November 7, 2024 8:00 AM ET Company Participants Kathryn Flynn - Corporate Controller James Green - Chairman, President and CEO Jennifer Cote - CFO Conference Call Participants Paul Knight -...
Harvard Bioscience Schedules Third Quarter 2024 Earnings Conference Call for November 7, 2024 at 8:00 AM ET
HOLLISTON, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended September 30, 2024 before the market opens on November 7, 2024, and will hold a conference call to...
2 Instruments Stocks to Watch From a Challenging Industry
The Zacks Instruments - Scientific industry participants like MTD and HBIO are gaining from strong life science, pharmaceutical and academic end-market demand despite the challenging macroeconomic environment.
Harvard Bioscience to Showcase Latest Solutions for Preclinical and Organoid Applications at Safety Pharmacology Society Annual Meeting
Solutions for CROs, pharma and biotechs streamline testing and enable fundamental advancements in preclinical and organoid focused therapy development Solutions for CROs, pharma and biotechs streamline testing and enable fundamental advancements in preclinical and organoid focused therapy development
Harvard Bioscience, Inc. to Participate in the Sidoti Small Cap Virtual Conference
HOLLISTON, Mass., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Jim Green, Chairman and Chief Executive Officer, and Jennifer Cote, Chief Financial Officer, will be participating in the Sidoti Small Cap Virtual Conference on...
Harvard Bioscience, Inc. (HBIO) Q2 2024 Earnings Call Transcript
Harvard Bioscience, Inc. (NASDAQ:HBIO ) Q2 2024 Earnings Conference Call August 8, 2024 10:00 AM ET Company Participants Kathryn Flynn - Corporate Controller James Green - Chairman, President and CEO Jennifer Cote - CFO Conference Call Participants Paul Knight -...
Harvard Bioscience Announces Second Quarter 2024 Financial Results
HOLLISTON, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the second quarter ended June 30, 2024.
Harvard Bioscience Schedules Second Quarter 2024 Earnings Conference Call for August 8, 2024 at 10:00 AM ET
HOLLISTON, Mass., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended June 30, 2024 before the market opens on August 8, 2024, and will hold a conference call to...
Harvard Bioscience, Inc. to Present and Host One-on-One Meetings at the 14th Annual East Coast IDEAS Conference on June 12, 2024
HOLLISTON, Mass., June 06, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Jim Green, Chairman and Chief Executive Officer, and Jennifer Cote, Chief Financial Officer, will be presenting to investors at the 14th Annual East Coast...
Harvard Bioscience, Inc. to Present at the Jefferies Global Healthcare Conference on June 5, 2024
HOLLISTON, Mass., May 23, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Jim Green, Chairman and Chief Executive Officer, and Jennifer Cote, Chief Financial Officer, will be presenting to investors at the Jefferies Global Healthcare Conference...
Source: https://incomestatements.info
Category: Stock Reports